Breast and gynecological cancer | Report Store

Disease Analysis: Triple-Negative Breast Cancer

TNBC is a relatively rare breast cancer subtype. It is characterized by the absence of estrogen and progesterone receptors, and does not involve the overexpression of HER2. TNBC is associated with poor prognosis, a high risk of local recurrence, and poor disease-free and cancer-specific survival. It accounts for roughly 14% of breast cancers.

September 15, 2020

Find out more

Disease Analysis: Ovarian Cancer

Ovarian cancer is defined as a group of tumors that originate in the ovaries. Epithelial ovarian cancer is the prevailing cause of death from gynecological malignancies in the Western world.

August 20, 2020

Find out more

Market Spotlight: Uterine Cancer

$1,318.00

This Market Spotlight report covers the uterine cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

July 21, 2020

Find out more

Disease Analysis: HR+/HER2- Breast Cancer

Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer is defined by the overexpression of estrogen or progesterone receptors, or both, and a lack of HER2 expression.

June 19, 2020

Find out more

HR+/HER2- Breast Cancer Pricing, Reimbursement, and Access

$2,995.00

Despite a high level of concern regarding spend on breast cancer medicines, access restrictions remain only mild to moderate. Spend in the indication is in the top three in oncology due to both medicines’ cost and high disease prevalence

October 16, 2018

Find out more

Breast cancer: HER2 Positive Forecast and Market Analysis to 2025

The approval of Herceptin (trastuzumab) in 1998 transformed the treatment of this aggressive disease, leading to increased disease-free progression and survival outcomes in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer.

May 9, 2018

Find out more

Cervical Cancer Disease Coverage Forecast and Market Analysis to 2024

Cervical cancer is a major gynecological cancer which involves uncontrolled cell division and tissue invasiveness of the female uterine cervix.

June 7, 2017

Find out more